PUBLISHER: TechSci Research | PRODUCT CODE: 2046566
PUBLISHER: TechSci Research | PRODUCT CODE: 2046566
Muscle Spasticity Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The global muscle spasticity market is projected to expand significantly, growing from USD 3.65 billion in 2025 to USD 5.41 billion by 2031, demonstrating a compound annual growth rate of 6.78%. This market encompasses a range of pharmaceutical treatments and medical devices specifically designed to alleviate involuntary muscle contractions, which are typically associated with various central nervous system disorders. Its growth is primarily fueled by the increasing global incidence of chronic neurological conditions, such as cerebral palsy and stroke, which necessitate ongoing therapeutic management to enhance patient mobility and quality of life.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 3.65 Billion |
| Market Size 2031 | USD 5.41 Billion |
| CAGR 2026-2031 | 6.78% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
For instance, the Multiple Sclerosis International Federation reported approximately 2.9 million individuals living with multiple sclerosis worldwide in 2024, creating a consistent demand for effective antispasmodic solutions. However, a major impediment to the market's broader expansion is the substantial cost of advanced therapies, including botulinum toxin injections and intrathecal baclofen pumps. These high expenses, combined with insufficient reimbursement policies in developing economies, restrict patient access to critical treatments and often lead healthcare providers to opt for more affordable, yet less effective, generic oral medications, thereby hindering revenue potential in these regions.
Market Driver
A primary catalyst for the muscle spasticity market's expansion is the increasing prevalence of chronic neurological disorders, which frequently result in spasticity following central nervous system damage. Conditions like stroke and traumatic brain injuries disrupt normal neural signaling, creating an urgent need for effective, long-term management strategies to prevent permanent muscle contractures. According to the World Health Organization's March 2024 study, neurological conditions collectively affect approximately 3.4 billion people globally, establishing them as a leading cause of disability and ensuring a sustained demand for therapeutic interventions.
For example, the National Spinal Cord Injury Statistical Center estimated around 305,000 cases of spinal cord injuries in the United States in 2024, a patient demographic heavily reliant on consistent antispasmodic care. Furthermore, the increasing adoption of botulinum toxin injectables represents a significant secondary driver, marking a clinical shift from systemic oral medications towards highly targeted focal therapies. These biologic treatments offer precise muscle relaxation with a reduced risk of systemic side effects, prompting increased utilization by specialists for refractory spasticity, as evidenced by AbbVie reporting global net revenues of $848 million for its therapeutic botulinum toxin portfolio in the third quarter of 2024.
Market Challenge
The global muscle spasticity market faces a significant restraint due to the prohibitive cost associated with advanced therapeutic interventions, particularly botulinum toxin injections and intrathecal baclofen pumps. These premium treatment modalities demand substantial financial commitment from both healthcare systems and individual patients. In numerous regions, existing reimbursement policies are often inadequate to fully cover the high expenses of these specialized biologics and medical devices. This financial gap frequently compels healthcare providers to prescribe more affordable generic oral medications, which, despite being accessible, are typically less effective in managing severe spasticity symptoms.
This economic disparity significantly limits market penetration, especially within developing economies where out-of-pocket expenses are a major barrier. The substantial economic burden of underlying conditions further exacerbates the situation; for instance, the World Stroke Organization estimated the global economic impact of stroke at approximately $890 billion annually in 2024. Such immense baseline healthcare costs make it challenging for payers to justify and approve additional high-cost spasticity therapies, directly reducing the adoption rates of advanced solutions and consequently restricting the market's overall revenue generation and growth potential.
Market Trends
A key trend reshaping spasticity management is the increasing adoption of robotic-assisted physical rehabilitation technologies, which enable high-intensity, repetitive gait training beyond what manual therapy can achieve. Advanced exoskeletons are increasingly being integrated into clinical practice to offer mechanical support and facilitate motor learning for patients suffering from spinal cord injuries and various neurological impairments. This shift towards automated rehabilitation is notably supported by improved reimbursement landscapes, which have significantly enhanced patient access to these sophisticated devices; for example, Lifeward Ltd. reported a 130% increase in ReWalk Personal Exoskeleton sales in 2024, directly attributing this growth to established Medicare coverage.
Concurrently, the proliferation of wearable neuromodulation and biofeedback devices is transforming care by moving it from intermittent clinical visits to continuous, home-based mobility solutions. These non-invasive technologies, often designed as bionic clothing, leverage artificial intelligence to deliver functional electrical stimulation that precisely corrects gait patterns and suppresses muscle spasms in real-time. The rapid market penetration of these user-friendly interfaces is clearly demonstrated by their expanding prescriber base; Cionic, for instance, announced in September 2025 that its Neural Sleeve technology had reached 1,500 prescribers nationwide, underscoring the robust demand for adaptive, wearable therapeutic interventions.
Key Market Players
- AbbVie Inc.
- Pfizer Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Eli Lilly and Company
- Bausch Health Companies Inc.
- Ipsen S.A.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
Report Scope
In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Muscle Spasticity Market, By Drug Type
- Baclofen
- Botulinum Toxin
- Diazepam
- Dantrolene Sodium
- Others
Muscle Spasticity Market, By Route of Administration
- Oral
- Intramuscular
- Others
Muscle Spasticity Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Muscle Spasticity Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Muscle Spasticity Market.
Available Customizations:
Global Muscle Spasticity Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Muscle Spasticity Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others)
- 5.2.2. By Route of Administration (Oral, Intramuscular, Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
- 5.3. Market Map
6. North America Muscle Spasticity Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Muscle Spasticity Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Muscle Spasticity Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Muscle Spasticity Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Muscle Spasticity Market Outlook
7. Europe Muscle Spasticity Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Muscle Spasticity Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Type
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Muscle Spasticity Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Type
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Muscle Spasticity Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Type
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Muscle Spasticity Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Type
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Muscle Spasticity Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Type
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Muscle Spasticity Market Outlook
8. Asia Pacific Muscle Spasticity Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Muscle Spasticity Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Type
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Muscle Spasticity Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Muscle Spasticity Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Type
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Muscle Spasticity Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Type
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Muscle Spasticity Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Type
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Muscle Spasticity Market Outlook
9. Middle East & Africa Muscle Spasticity Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Muscle Spasticity Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Type
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE Muscle Spasticity Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Type
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa Muscle Spasticity Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Type
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia Muscle Spasticity Market Outlook
10. South America Muscle Spasticity Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Muscle Spasticity Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia Muscle Spasticity Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Type
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina Muscle Spasticity Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Type
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Muscle Spasticity Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global Muscle Spasticity Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. AbbVie Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. Pfizer Inc.
- 15.3. Novartis AG
- 15.4. F. Hoffmann-La Roche Ltd.
- 15.5. Merck & Co., Inc.
- 15.6. Eli Lilly and Company
- 15.7. Bausch Health Companies Inc.
- 15.8. Ipsen S.A.
- 15.9. Sanofi S.A.
- 15.10. Teva Pharmaceutical Industries Ltd.
16. Strategic Recommendations
17. About Us & Disclaimer
